Various volatile organic compounds (VOCs) are known to be toxic. Although exhaled VOC patterns change in obstructive sleep apnea (OSA) patients, individual VOC profiles are not fully determined. The primary outcome was VOC characterizations; secondary outcomes included their relationships with sleep and clinical parameters in OSA patients. We prospectively examined 32 OSA patients with an apnea-hypopnea index (AHI) ! 15 by full polysomnography, and 33 age-and sex-matched controls without obvious OSA symptoms. Nine severe OSA patients were examined before and after continuous positive airway pressure (CPAP) treatment. By applying a method which eliminates environmental VOC influences, exhaled VOCs were identified by gas chromatography (GC)-mass spectrometry, and their concentrations were determined by GC. Exhaled aromatic hydrocarbon concentrations (toluene, ethylbenzene, p-xylene, and phenylacetic acid) in the severe OSA groups (AHI ! 30) and exhaled saturated hydrocarbon concentrations (hexane, heptane, octane, nonane, and decane) in the most severe OSA group (AHI ! 60) were higher than those in the control group. Exhaled isoprene concentrations were increased in all OSA groups (AHI ! 15); acetone concentration was increased in the most severe OSA group. Ethylbenzene, p-xylene, phenylacetic acid, and nonane concentrations were increased according to OSA severity, and correlated with AHI, arousal index, and duration of percutaneous oxygen saturation (SpO 2 ) 90%. Multiple regression analyses revealed these 4 VOC levels were associated with the duration of SpO 2 90%. Isoprene and acetone decreased after CPAP treatment. OSA increased some toxic VOCs, and some correlated with OSA severity. CPAP treatment possibly ameliorates these productions.
the brain (the main components of which are lipids and proteins), morphological changes suggesting serious brain damage occur in patients with OSA, (Macey et al., 2002 (Macey et al., , 2008 although a causal link between these morphological changes and OSA has not been established to date (Lim and Pack, 2014) . The various clinical symptoms and complications of OSA resemble, to a limited extent, the effects of exposure to certain volatile organic compounds (VOCs), especially those of some aromatic VOCs.
VOCs consist primarily of aromatic hydrocarbons, alicyclic hydrocarbons, chain hydrocarbons (saturated hydrocarbons: alkanes, and unsaturated hydrocarbons: dienes), ketones, and alcohols. Benzene, toluene, ethylbenzene, and xylene, which belong to the aromatic group and are known as BTEX, are especially notable as hazardous air pollutants (Kheirbek et al., 2012) . Benzene has carcinogenic potential (Loh et al., 2007) , and toluene, ethylbenzene, and xylene exert toxic effects on the respiratory, neurological, and other systems (Agency for Toxic Substances and Disease Registry, 2016a,b,c) . Toluene is an inhibitor of central nervous system activity that causes memory loss and progressive brain and nerve damage (Agency for Toxic Substances and Disease Registry, 2016a) . Animal models of chronic inhalation exposure to ethylbenzene have identified the kidney as a sensitive target organ (Agency for Toxic Substances and Disease Registry, 2016b) . Workers chronically exposed to mixed xylenes reported significantly increased subjective symptoms, including increased anxiety, forgetfulness, and inability to concentrate (Uchida et al., 1993) .
Changes in exhaled VOC patterns have been demonstrated in patients with OSA using an electronic nose (Dragonieri et al., 2015; Greulich et al., 2013; Incalzi et al., 2015) . Greulich et al. (2013) reported accurate discrimination between patients with OSA and controls regarding changes in VOC patterns after continuous positive airway pressure (CPAP) treatment using an electronic nose. Although these studies previously demonstrated changes in exhaled VOC patterns in patients with OSA, electronic nose technology cannot characterize and determine each VOC individually. There are few reports characterizing changes in VOCs in patients with OSA, though the amount of expired pentane reportedly increased (Olopade et al., 1997a) .
Lipid peroxidation induced by reactive oxygen species due to inflammation may play a pivotal role in the production of pentane and ethane (Miekisch et al., 2004) , which have been reported to be elevated in patients with OSA (Olopade et al., 1997a) , chronic obstructive pulmonary disease (Paredi et al., 2000a) , asthma (Olopade et al., 1997b; Paredi et al., 2000b) , and interstitial lung disease (Kanoh et al., 2005) , as well as in critically ill patients (Schubert et al., 1998) . The 2 possible sources of expired VOCs are exogenous and endogenous VOCs (van de Kant et al., 2012) . Exogenous VOCs are taken up as environmental pollutants via inspiration, ingestion, or percutaneous absorption. Subsequently, these compounds are expired or excreted with or without being metabolized (van de Kant et al., 2012) . Endogenous VOC-generating pathways have been proposed for a few VOCs (Buszewski et al., 2007; Miekisch et al., 2004) . Isoprene is thought to be formed along the mevalonic pathway of cholesterol synthesis. Dimethylallyl pyrophosphate is converted to isoprene via an acid-catalyzed elimination reaction in the in vitro system (Deneris et al., 1984) , while it is unknown whether this nonenzymatic reaction accounts for isoprene formation under physiologic conditions (Miekisch et al., 2004) . Acetone is formed by decarboxylation of acetoacetate, which is derived from lipolysis or lipid peroxidation (Buszewski et al., 2007; Miekisch et al., 2004) .
We hypothesized that VOCs may increase according to OSA severity and that their concentrations may reach toxic levels in vivo, which could influence various pathophysiological aspects of this condition. We aimed to identify individual VOCs and determine their exhaled concentrations according to OSA severity using a method to eliminate environmental VOC influences. Moreover, the effects of CPAP treatment on VOC production were investigated in patients with severe OSA.
MATERIALS AND METHODS

Study Population
Between August 2010 and November 2011, patients diagnosed with OSA who were admitted to the Sleep Center of Tokai University Hospital (Isehara, Japan) and who met the following criteria were prospectively registered. The study criteria were as follows: patients with an apnea-hypopnea index (AHI) ! 15 diagnosed by full polysomnography (PSG) and who were admitted one day before the scheduled day of a VOC analysis. The primary outcome was characterization of VOCs and their expired concentrations; secondary outcomes included the relationships between VOC concentrations and sleep and clinical parameters.
Patients with respiratory failure, overt liver dysfunction, renal failure (serum creatinine >1.5 mg/dl), heart failure, symptomatic brain infarction, uncontrolled diabetes mellitus, chronic infection, symptomatic collagen disease, or symptomatic chronic disease were excluded. Patients were recruited as follows. Outpatients with suspected OSA based on symptoms (excessive daytime sleepiness [EDS] , snoring, and nocturnal apnea) were examined using the Epworth Sleepiness Scale (ESS) and a portable sleep-monitoring device (Apnomonitor mini, CHEST M.I., Inc., Hongou, Tokyo, Japan), which was equipped with a percutaneous oxygen saturation (SpO 2 ) monitor, a piezo band to assess ventilatory movements, and a nasal/oral thermistor flow sensor. Pulmonary function tests, electrocardiograms, and chest radiographs were also performed to diagnose any pulmonary or heart disease complications. Patients suspected of having moderate-to-severe OSA (AHI ! 5 with EDS or AHI ! 10 without symptoms) based on the aforementioned portable sleep-monitoring device were admitted. On the first night, the patients underwent a full PSG examination. On the second morning, blood pressure was measured, and a 5-ml blood sample was drawn before breakfast for laboratory examinations. The clinical and laboratory profiles of the patients were assessed. The fasting duration was over 10 hours (from 8:00 PM the previous night to 6:00 AM the next morning).
Thirty-three age-and sex-matched controls without subjective EDS, snoring, and nocturnal apnea, were recruited among hospital staff, mostly, and volunteers. However, a questionnaire was not used in the control subjects.
The VOC concentrations of patients with severe OSA (AHI ! 30) who commenced CPAP treatment between February 2015 and September 2015 were examined before and at least 1 month after the beginning of the CPAP treatment. The VOCs of these patients were measured in an outpatient ward. No sham CPAP was used in the control group.
Written informed consent was obtained from all patients and controls. This protocol was performed in accordance with the Declaration of Helsinki and was approved by the Tokai University School of Medicine institutional review board (Isehara, Japan).
PSG
The PSG machine (SleepWatcher E series, Teijin, Tokyo, Japan) consisted of an electroencephalogram (EEG; C3-M2, C4-M1, O1-M2, and O2-M1); electrooculogram (EOG; LOC-M2, and ROC-M1); submental and bilateral anterior tibialis electromyograms; measurements of heart rate, SpO 2 , and nasal pressure; a nasal/oral thermistor; piezo bands to detect thoracic and abdominal movement; an anterior neck microphone to record snoring intensity; and placement of a body position sensor. All PSG data were electronically transmitted to the central monitor display and stored on hard drives. Sleep stages and wakefulness were defined according to the Rechtschaffen and Kales (1968) criteria. Apnea, hypopnea, AHI, arousal index, and respiratory disturbance index were defined according to a scoring system used for sleep and associated events (Berry et al., 2012) .
Analysis of Expired VOCs
The system consisted of air purification, collection of expired gases, accumulation of expired gases, and analysis by gas chromatography (GC) (Kanou et al., 2013; Nagaoka et al., 2015) . Air was purified with a purification tube (a stainless steel pipe with a 4.2-mm internal diameter and 1000-mm length) filled with stainless steel wool in a cooling tank at approximately À80 C.
The purified air flowing out of the tube was collected in a polyvinyl fluoride film bag (Tedlar Bag, DuPont, Wilmington, Delaware, USA). Although sitting and wearing a mask (King Mask, King Systems, Noblesville, Indiana, USA), each subject was instructed to breathe stably. The air collection equipment had a 1-way valve and filter (BB50T Breathing Circuit Filter, Pall Corporation, Port Washington, New York, USA). The subjects inspired and exhaled 10 l of purified air, which was enough to eliminate environmental VOCs from their lungs. Each subject then inspired and exhaled 5 l of purified air, and the expired gases were collected and concentrated in a stainless steel tube via aspiration through a tube cooled to approximately À80 C using a pump, similar to the air purification process. After heating to 80 C for 30 min, the expired and concentrated gases released from the stainless steel tube were analyzed by GC with a flame ionization detector (Kanoh et al., 2005) . We considered a peak appearing at the same retention time to correspond to the same VOC. To determine the selected target VOCs for our system, we analyzed the expired gases using a GCmass spectrometry system (HP6890 and HP5973, Agilent Technologies, Santa Clara, California, USA) (Supplementary Figure S1 ). Standard reference curves for target VOCs were created using standard VOC gas samples (Japan Fine Products Corporation, Kawasaki, Japan) at 100 or 10 ppb to determine their concentrations.
To measure VOCs in the exhaled air of patients before and after CPAP treatment on an outpatient ward, we used a simple needle trap sampling method (Strating et al., 2013) for simple quantitative VOC analyses. The patients inspired and exhaled 10 l of purified air, then inspired and exhaled 5 l of purified air, and the expired gases were collected. A needle trap device sampler (Shinwa NeedlEx NTD Sampler, Shinwa, Fushimi-ku, Kyoto, Japan) was used for rapid quantitative sampling. Exhaled isoprene and acetone concentrations were measured stably with this method.
Statistical Analysis
The sample size was based on estimations of a control SD of 2.0, difference in mean value of 3.0, a error of 0.05, b error of 0.20, and a control: patient ratio of 4.0. The determined sample size was 20 controls and 7 patients.
The data are expressed as the means 6 SD. The significance of intergroup differences was determined by the Kruskal-Wallis test, and the Dunn test was used to identify significant differences. The chi-squared test was applied to compare categorical variables. Pearson's coefficient test was used to identify relationships between variables. Based on the results of this analysis, multiple regression analyses were performed. The MannWhitney U test was used to compare continuous variables between 2 groups. Wilcoxon's signed-rank test was used to compare VOCs before and after CPAP treatment. Differences were considered statistically significant at P < .05. All statistical analyses were performed using Stat Flex ver. 6.0 statistical software (Artech Co., Ltd. Osaka, Japan).
RESULTS
Baseline Characteristics
In total, 77 patients were registered; all were approached to participate in this clinical study, and 3 OSA patients declined to participate. Therefore, data from 32 patients with OSA and 33 control subjects were analyzed, and they ranged in age from 30 to 76 years (Table 1) . Furthermore, 9 patients with severe OSA (AHI ! 30) were registered in order to measure VOC concentrations before and after CPAP treatment.
We classified patients with OSA into 3 groups: a moderate OSA group consisting of patients with an AHI of 15-30 (15 AHI < 30) (AHI 15-30), a severe OSA group consisting of patients with an AHI of 30-60 (30 AHI < 60) (AHI 30-60), and the most severe OSA group consisting of patients with an AHI of 60 and above (60 AHI) (AHI 60À). There were 10 patients in the AHI 15-30 group, 15 patients in the AHI 30-60 group, and 7 patients in the AHI 60-group. There were no differences in age, sex, or smoking status between the control and OSA groups (Table 1) . Smoking status is known to influence exhaled VOC concentrations (Chambers et al., 2011) . The body mass index (BMI) of the AHI 15-30 group was not significantly different from that of the control group. However, the BMIs of the AHI 30-60 and AHI 60À groups were significantly higher than that of the control group. There were no BMI differences among the OSA groups (Table 1) . We could not match the BMI of the control group with those of the AHI 30-60 and AHI 60À groups because the BMI of the normal Japanese population is very low. The average BMI range for a Japanese male is 21.9-23.4 kg/m 2 , and that for a Japanese female is 20.3-22.9 kg/m 2 (Yanai et al., 1997) while the average BMIs were very high in the AHI 30-60 group (28.0 kg/m 2 ) and AHI 60À group (30.5 kg/m 2 ) in this study.
There were no differences in neck circumference, waist circumference, systolic blood pressure (SBP), or diastolic blood pressure (DBP) among the OSA groups (Supplementary Table  S1 ). Moreover, there were no differences among the AHI 15-30, 30-60, and 60À groups in ESS score, vital capacity, percent vital capacity, forced expiratory volume in 1 s, or fasting plasma glucose (FPG), nor in the serum levels of HbA1c, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides (Supplementary Table S1 ). The PSG data, however, differed markedly among these 3 groups (Supplementary Table S2 ). The arousal index was higher (48.3 6 13.6) in the AHI 60À group than in the AHI 15-30 group (25.1 6 6.3), and the minimum SpO 2 (72 6 6%) in the AHI 60À group was significantly lower than that in the AHI 15-30 group (82 6 6%).
Expired VOC Concentrations
The expired VOC concentrations of the study groups are shown in Table 2 (homocyclic compounds), Figs. 1 and 2 ). The concentrations of ethylbenzene, p-xylene, and phenylacetic acid were increased according to OSA severity ( Figure 2 , Table 2 ). Among the saturated hydrocarbons, the expired concentrations of hexane (C 6 H 14 ), heptane (C 7 H 16 ), octane (C 8 H 18 ), nonane (C 9 H 20 ), and decane (C 10 H 22 ) were higher in the most severe OSA group (AHI ! 60) than in the control group (Figure 1 , Table 3 ). The concentrations of heptane and nonane were higher in all OSA groups (AHI ! 15) than in the control group. The nonane concentration increased according to OSA severity ( Figure 2 , Table 3 ). Isoprene concentrations were higher in all OSA groups than in the control group ( Figure 1 , Table 3 ). The acetone concentration in the most severe OSA (AHI > 60) group was higher than that in the control group ( Figure 1 , Table 2 ). There were no differences in benzene, cyclohexane, or ethanol among the study groups (Figure 1 , Tables 2  and 3) .
Correlations between OSA Severity-Dependent VOCs and Clinical Parameters
Correlations between clinical parameters and ethylbenzene, p-xylene, phenylacetic acid, and nonane are shown in Supplementary Table S3 . Ethylbenzene and p-xylene were significantly correlated with BMI (ethylbenzene, r ¼ 0.37, P ¼ .04; and p-xylene, r ¼ 0.38, P ¼ .03), while phenylacetic acid and nonane were not. Ethylbenzene (r ¼ 0.50, P < .01), p-xylene (r ¼ 0.37, P ¼ .03), and phenylacetic acid (r ¼ 0.47, P < .01) were significantly correlated with neck circumference, while the correlation between nonane and neck circumference was not significant. Ethylbenzene (r ¼ 0.36, P ¼ .04) and phenylacetic acid (r ¼ 0.37, P ¼ .04) were significantly correlated with waist circumference, while p-xylene and nonane were not (Supplementary Table S3 ).
These 4 VOCs were not correlated with SBP or DBP or with FPG, HbA1c, LDL cholesterol, HDL cholesterol, or triglyceride levels (Supplementary Table S3 ). Scatter plots of Pearson's correlation coefficients between sleep parameters and OSA severity-dependent VOCs are shown in Figure 3 . AHI was correlated with ethylbenzene (r ¼ 0.49, P < .01), p-xylene (r ¼ 0.44, P ¼ .01), phenylacetic acid (r ¼ 0.45, P < .01), and nonane (r ¼ 0.47, P < .01). The duration of SpO 2 90% was correlated with ethylbenzene (r ¼ 0.56, P < .01), p-xylene (r ¼ 0.51, P < .01), phenylacetic acid (r ¼ 0.50, P < .01), and nonane (r ¼ 0.46, P < .01). The arousal index was also correlated with ethylbenzene (r ¼ 0.48, P < .01), p-xylene (r ¼ 0.42, P ¼ .02), phenylacetic acid (r ¼ 0.38, P ¼ .03), and nonane (r ¼ 0.39, P ¼ .03).
Correlations between OSA Severity-Dependent VOCs and Other VOC Concentrations
Pearson's correlation coefficients between OSA severitydependent VOCs and other VOC concentrations are shown in Supplementary Table S4 . Toluene was correlated with ethylbenzene (r ¼ 0.44, P ¼ .01), p-xylene (r ¼ 0.52, P < .01), phenylacetic acid (r ¼ 0.56, P < .01), and nonane (r ¼ 0.42, P ¼ .02). Heptane was correlated with p-xylene (r ¼ 0.38, P ¼ .03) and nonane (r ¼ 0.37, P ¼ .04) but not with ethylbenzene or phenylacetic acid. Decane was correlated with ethylbenzene (r ¼ 0.54, P < .01), p-xylene (r ¼ 0.63, P < .01), phenylacetic acid (r ¼ 0.63, P < .01), Isoprene (H), acetone (I), and ethanol (J) are an unsaturated hydrocarbon, a ketone, and an alcohol, respectively (lower panels). Data are expressed as the mean 6 SD. *P < .05 and ** P < .01 versus control among all groups. †P < .05 versus AHI 15-30 among OSA groups. The significance was determined by the Kruskal-Wallis test followed by the Dunn test. and nonane (r ¼ 0.72, P < .01). Acetone was correlated with ethylbenzene (r ¼ 0.46, P < .01), p-xylene (r ¼ 0.40, P ¼ .03), and phenylacetic acid (r ¼ 0.40, P ¼ .02) but not with nonane.
There were strong correlations (r > 0.06, P < .01) between ethylbenzene, p-xylene, phenylacetic acid, and nonane (Figure 4 , Supplementary Table S4). Ethylbenzene was significantly correlated with p-xylene (r ¼ 0.89), phenylacetic acid (r ¼ 0.86), and nonane (r ¼ 0.81); p-xylene was correlated with phenylacetic acid (r ¼ 0.82), nonane (r ¼ 0.92), and decane (r ¼ 0.63). Phenylacetic acid was correlated with nonane (r ¼ 0.77) and decane (r ¼ 0.63). Nonane was correlated with decane (r ¼ 0.72).
Multiple Regression Analyses Using the OSA SeverityDependent VOC Concentration as a Dependent Variable
To examine the influences of sleep and clinical parameters on OSA severity-dependent VOC production, ethylbenzene, pxylene, phenylacetic acid, and nonane concentrations were chosen as dependent parameters for multiple regression analyses (Table 4) . According to the results of applying Pearson's correlation coefficients (Supplementary Table S3 , Figure 3) , BMI, age, and sex were chosen as independent variables among clinical parameters, and AHI, duration of SpO 2 90%, and arousal index were chosen as independent variables among sleep parameters. The analyses demonstrated that the duration of SpO 2 90% was associated with ethylbenzene, p-xylene, phenylacetic acid, and nonane levels independent of BMI, age, and sex (Table 4) .
Effects of BMI on Exhaled VOC Concentrations
BMI is known to be related to OSA (Young et al., 2002 (Young et al., , 2005 . We could not, however, match the BMIs of the control group and OSA patients in this study. Therefore, exhaled VOC concentrations were examined by applying BMI stratification (Table 5; Figs. 5-7). Moreover, within the same BMI group (BMI < 25, 25 BMI < 30, 30 BMI), exhaled VOC concentrations were compared between the controls and OSA patients (Figs. 5 and 6; Table 5 ). In the BMI < 25, the concentrations of ethylbenzene, pxylene, phenylacetic acid, heptane, octane, nonane, decane, and isoprene of the OSA patients were higher than those of the control subjects ( Figure 5 ). In the 25 BMI < 30, the concentrations of ethylbenzene, phenylacetic acid, cyclohexane, octane of the OSA patients were higher than those of the control subjects ( Figure 6 ). These results indicate that the production of these VOCs is increased by OSA.
In order to analyze the effects of BMI on VOC production, VOC concentrations were compared between the BMI < 25 and the 25 BMI < 30 subjects in the control group (Figure 7) . The cyclohexane concentration of the 25 BMI < 30 subjects was lower than that of the BMI < 25 subjects. The concentrations of decane, isoprene and acetone of the 25 BMI < 30 subjects were higher than those of the BMI < 25 subjects. These results suggest that the production of these VOCs is influenced by BMI. The concentrations of benzene, toluene, ethylbenzene, p-xylene, phenylacetic acid, hexane, heptane, octane, nonane, and ethanol did not differ between the BMI < 25 and the 25 BMI < 30
, phenylacetic acid (C), and nonane (D) concentrations in the study groups. The concentrations of these 4 VOCs were increased according to OSA severity. The boxes express the mean 6 SD. *P < .05 and **P < .01 versus the controls among all groups. †P < .05 and † †P < .01 versus the AHI 15-30 group, and ‡P < .05 versus the AHI 30-60 group among the OSA groups. The significance was determined by the Kruskal-Wallis test followed by the Dunn test.
subjects, suggesting that the production of these VOCs might not be influenced by BMI.
VOC Concentrations before and after CPAP Treatment
A total of 9 patients with severe OSA (AHI ! 30) were registered. VOC concentrations were measured before and after CPAP treatment in these 9 patients (Table 6 ). Exhaled acetone and isoprene concentrations were decreased after CPAP treatment (Figure 8 ).
DISCUSSION
Using an electronic nose, exhaled VOCs were demonstrated to change in patients with OSA (Dragonieri et al., 2015; Greulich et al., 2013; Incalzi et al., 2015) . The discrimination between patients with OSA and healthy subjects using this technology was based on pattern recognition, and individual VOCs were not fully elucidated in previous studies. In this study, individual VOCs and their exhaled concentrations in patients with OSA were determined according to OSA severity. The production of toxic VOCs was increased in vivo in patients with OSA, and some VOC concentrations rose as OSA became more severe.
These OSA-related VOCs might be useful as biomarkers of OSA, assuming that environmental VOC exposure can be eliminated. Nocturnal hypoxia was considered to be the main factor contributing to increased VOC production, based on multiple regression analyses. BMI might also contribute to the production of some VOCs, while OSA further increases the production of OSA-dependent VOCs. CPAP treatment is suggested to ameliorate the increased productions of these VOCs. This study demonstrated VOCs, especially BTEX components, to be present at high levels in vivo in the most severe OSA group. There are, however, no reports concerning tissue VOC concentrations related to actual toxicities along with exhaled VOC concentrations in the living state in either animal models or humans. Therefore, we have no information regarding whether or not the estimated concentrations are toxic. High expired levels of both xylene and ethylbenzene reflect extremely high brain, adipose tissue, kidney, liver, and muscle concentrations, indicating that long-term continuous intrinsic exposure to these aromatic VOCs occurs in vivo in patients with severe OSA. Xylenes (para, meta, and ortho) exert harmful effects on the nervous system with inhalation exposure and on the kidneys with oral exposure (Agency for Toxic Substances and Disease Registry, 2016c). In humans, chronic inhalation exposure to mixed xylenes primarily results in neurological effects, including cognitive dysfunction, headache, dizziness, fatigue, and loss of coordination (Agency for Toxic Substances and Disease Registry, 2016c; U.S. Environmental Protection Agency, 2014). The minimal risk level for chronic inhalation exposure (>1 year) to mixed xylenes is reportedly 50 ppb (Agency for Toxic Substances and Disease Registry, 2016c). The minimal risk level for chronic inhaled ethylbenzene exposure was determined to be 60 ppb (Agency for Toxic Substances and Disease Registry, 2016b). Ethylbenzene has harmful effects on hearing, the kidneys, and the liver (Agency for Toxic Substances and Disease Registry, 2016b). Concentrations of p-xylene and ethylbenzene in various tissues are determined by blood:air and tissue:blood partition coefficients in mammals (Haddad et al., 2000; Kumarathasan et al., 1998) . Brain p-xylene and ethylbenzene concentrations are estimated to be 120-and 100-fold higher than expired concentrations, respectively (Haddad et al., 2000; Kumarathasan et al., 1998) . Similarly, in the adipose tissue, kidney, liver, and muscle, the respective estimated concentrations are 3000-, 130-, 230-, and 110-fold higher than the expired p-xylene concentration and 2500-, 120-, 210-, and 97-fold higher than the expired ethylbenzene concentration (Haddad et al., 2000; Kumarathasan et al., 1998) .
Lipid peroxidation induced by reactive oxygen species due to inflammation in OSA might play an important role in saturated hydrocarbon production. Exhaled hexane, heptane, octane, nonane, and decane were elevated in patients with OSA as compared with controls in our study. These VOCs are all saturated hydrocarbons, similar to ethane and pentane. Exhaled ethane and pentane are known to be products of lipid peroxidation induced by reactive oxygen species due to inflammation (Kanoh et al., 2005; Miekisch et al., 2004; Olopade et al., 1997b; Paredi et al., 2000a,b; Schubert et al., 1998) .
However, isoprene is an unsaturated hydrocarbon. Exhaled isoprene was also elevated in patients with moderate-to-severe OSA in this study. Plants that emit isoprene are better able to tolerate sunlight-induced rapid heating of leaves as well as ozone and other reactive oxygen species (Sharkey et al., 2008) , and isoprene reacts very rapidly with hydroxyl radicals (Sharkey et al., 2008) . Exhaled isoprene was reportedly decreased, while exhaled pentane was increased in acute respiratory distress syndrome Abbreviations: OSA, obstructive sleep apnea; VOC, volatile organic compound; BMI, body mass index. All subjects including OSA patients and control subjects were divided into 3 groups according to BMI (the BMI < 25, 25 BMI < 30, and 30 BMI groups), and OSA patients and control subjects were further divided in the same BMI group. Data are expressed as the mean 6 SD. #P < .05 for comparison within the control group between BMI < 25 and 25 BMI < 30. †P < .05 and † †P < .01 for comparison between the control and the OSA groups in each BMI group. P-value for comparisons among all groups (the BMI < 25, 25 BMI < 30, and 30 BMI groups). *P < .05 and **P < .01 versus the BMI < 25 group for all groups. There were no control subjects with BMI ! 30. P $ -value for comparisons among OSA patients (the BMI < 25, 25 BMI < 30, and 30 BMI OSA groups), ie, excluding the control subjects. There were no differences in any of the VOCs among the BMI < 25, 25 BMI < 30, and 30 BMI groups of OSA patients. The significance of intergroup differences was determined by the Kruskal-Wallis test, and the Dunn test was used to identify significant differences. The Mann-Whitney U test was used to compare between 2 groups.
FIG. 5.
VOC concentrations (ppb) in subjects with BMI < 25.The VOC concentrations were compared between the control and the OSA subjects with BMI < 25. The con-
and isoprene (L) were higher in the OSA patients than in the control subjects. Data are expressed as the mean 6 SD. †P < .05 and † †P < .01 for comparison between the control and the OSA subjects. The Mann-Whitney U test was used to compare these 2 groups.
FIG. 6. VOC concentrations (ppb) in subjects with BMI from 25 to 30. The VOC concentrations were compared between the control and the OSA subjects with 25 BMI < 30. The concentrations of ethylbenzene (C), phenylacetic acid (E), cyclohexane (F), and octane (I) were higher in the OSA patients than in the control subjects. Data are expressed as the mean 6 SD. †P < .05 and † †P < .01 for comparison between the control and the OSA subjects. The Mann-Whitney U test was used to compare these 2 groups.
FIG. 7.
Comparison of VOC concentrations (ppb) between the BMI < 25 and the 25 BMI < 30 subjects in the control group. In order to analyze the effects of BMI on VOC production, VOC concentrations were compared between the BMI < 25 and the 25 BMI < 30 subjects in the control group. The cyclohexane (F) concentration of the 25 BMI < 30 subjects was lower than that of the BMI < 25 subjects. The concentrations of decane (K), isoprene (L), and acetone (M) were higher in the 25 BMI < 30 subjects than in the BMI < 25 subjects. Data are expressed as the mean 6 SD. #P < .05 for comparison between the BMI < 25 and the 25 BMI < 30 subjects in the control group. The Mann-Whitney U test was used to compare these 2 groups. Arousal index (/h) before CPAP after CPAP 45 6 6 9 (100) 2/5/2 32.2 6 2.8 71.0 6 30.9 154.9 6 90.4 48.7 6 20.1 13.3 6 14.7* 4.1 6 3.6** 9.9 6 3.4** Abbreviations: OSA, obstructive sleep apnea; CPAP, continuous positive airway pressure; BMI, body mass index; AHI, apnea-hypopnea index. Data are expressed as the mean 6 SD. *P < .05 and **P < .01 for comparison of the data obtained before and after CPAP treatment. Smoking status and BMI did not change after versus before CPAP treatment. Wilcoxon's signed-rank test was used for comparisons of parameters before and after CPAP treatment.
FIG. 8.
Changes in exhaled acetone and isoprene concentrations after CPAP treatment. Exhaled acetone and isoprene concentrations of patients with severe OSA whose AHIs were >30 were measured before and after >1 month of CPAP treatment. Concentrations of acetone and isoprene were decreased after CPAP treatment.
Wilcoxon's signed-rank test was used to compare acetone and isoprene concentrations before and after CPAP treatment. (Schubert et al., 1998) . The physiological significance of isoprene produced in vivo awaits elucidation in future experiments. The strong correlations between ethylbenzene, xylene, phenylacetic acid, and nonane suggest that similar mechanisms induced the formation of these VOCs. Most notably, the correlation coefficient between p-xylene and nonane was 0.92, and that between p-xylene and ethylbenzene was 0.89, suggesting that the origins of these VOCs could be the same. Further studies are required to understand the mechanisms of production of these VOCs using other study models (e.g., animal models of intermittent hypoxia). The specific origins and production mechanisms of these VOCs could not be elucidated by this study. OSA severity was reportedly associated with increased cancer incidence and mortality (Campos-Rodriguez et al., 2013; Mart ınez-Garc ıa et al., 2014; Nieto et al., 2012) . Colorectal, prostate, lung and breast cancers were reported to be associated with OSA in large cohort studies (Campos-Rodriguez et al., 2013; Mart ınez-Garc ıa et al., 2014) . Clarification of elevated aromatic VOC contributions to cancer occurrence might be warranted. Moreover, a large prospective study is necessary in order to examine whether or not elevated expired VOC concentrations are associated with various OSA complications.
Limitations of this study include the lack of full PSG studies of the control group. Furthermore, the lack of a high BMI control group is a limitation of this study. We were unable to match the BMI of the control group with those of the AHI 30-60 and AHI 60À groups. Instead, we stratified the subjects by BMI to examine the effects of BMI on each VOC production. Increasing BMI was associated with higher productions of some VOCs, while OSA further increased the productions of some OSA-related VOCs in the same BMI group.
In conclusion, we characterized the exhaled VOCs of patients with OSA and elucidated relationships of each VOC with sleep and clinical parameters using an air purification method to eliminate environmental VOC influences. This study is the first to demonstrate aromatic hydrocarbons (toluene, ethylbenzene, p-xylene, and phenylacetic acid), saturated hydrocarbons (hexane, heptane, octane, nonane, and decane), isoprene, and acetone to be elevated in patients with OSA. These VOCs might serve as OSA-biomarkers. Ethylbenzene, p-xylene, phenylacetic acid, and nonane, especially, were considered to be OSA severity-related VOCs. Hypoxia induced by severe OSA might increase the production of these VOCs. OSA severity-related VOCs showed strong correlations with each other, suggesting the existence of similar induction mechanisms, which should be studied in the future. CPAP treatment might ameliorate the production of these VOCs. This study has provided the novel insight that OSA induces toxic VOC production. A further large prospective study is necessary to explore the influences of VOCs on various complications in patients with OSA.
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